Aclaris Therapeutics, Inc. (ACRS) Gross margin 2017–2025
Aclaris Therapeutics, Inc. (ACRS) gross margin by fiscal year — reported gross profit divided by reported revenue.
73.3%FY2025 · since FY2017: 28.3% → 73.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 73.3% | -11.8 pp |
| FY2024 | 85.1% | -4.0 pp |
| FY2023 | 89.0% | +2.6 pp |
| FY2022 | 86.5% | +56.2 pp |
| FY2021 | 30.3% | +9.5 pp |
| FY2020 | 20.8% | +16.7 pp |
| FY2019 | 4.1% | -48.6 pp |
| FY2018 | 52.7% | +24.4 pp |
| FY2017 | 28.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice